MET and neoplasm: This dosing level is consistent with studies of tepotinib in other tumour types, and in Asian patients with HCC with MET overexpression.24,28,30 Preliminary anti-tumour activity was observed in Phase 1b with tepotinib: two patients achieved PR and four patients achieved SD.